GlassScriptPhysician profile
John D Roddenberry
NPI 1215985221
$5,943.93
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2020: $236 · 2021: $591 · 2022: $1,797 · 2023: $1,626 · 2024: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,062 · Education: $60.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,061.58 |
| Education | $60.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,478.78 | 2019-2024 | Skyrizi, Linzess, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $591.88 | 2019-2024 | Xifaxan |
| Qol Medical, LLC | $425.07 | 2019-2024 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $373.96 | 2019-2023 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $259.54 | 2019-2023 | Entyvio, Gattex |
| Pfizer INC. | $223.59 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $167.94 | 2019-2023 | Dificid, Zinplava |
| Celgene Corporation | $148.22 | 2019-2022 | |
| Evoke Pharma, INC. | $125.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $118.90 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $114.08 | 2019-2023 | Ocaliva |
| Genzyme Corporation | $98.64 | 2022-2023 | |
| Cook Medical LLC | $96.17 | 2019 | |
| Thd America, INC. | $91.10 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $87.55 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $57.38 | 2019 | |
| Redhill Biopharma INC. | $51.82 | 2021-2022 | |
| Mauna Kea Technologies, INC. | $48.16 | 2023 | |
| Lilly USA, LLC | $33.19 | 2023-2024 | Omvoh |
| Ucb, INC. | $32.16 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $30.47 | 2023 | |
| Braintree Laboratories, INC. | $30.30 | 2022-2023 | Suflave |
| Intra-Sana Laboratories | $30.18 | 2021 | |
| Allergan, INC. | $28.37 | 2019-2020 | |
| Boston Scientific Corporation | $27.89 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $27.46 | 2024 | |
| Pharmacosmos Therapeutics INC. | $24.91 | 2023 | Monoferric |
| Convatec INC. | $23.61 | 2024 | |
| Gilead Sciences, INC. | $22.71 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.82 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $19.99 | 2023 | Andexxa |
| Shionogi INC | $19.05 | 2019 | |
| Shire North American Group INC | $15.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Roddenberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.